A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma

BACKGROUND: Quilizumab, a humanized IgG1 monoclonal antibody, targets the M1-prime segment of membrane-expressed IgE, leading to depletion of IgE-switched and memory B cells. In patients with mild asthma, quilizumab reduced serum IgE and attenuated the early and late asthmatic reaction following who...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Jeffrey M., Maciuca, Romeo, Bradley, Mary S., Cabanski, Christopher R., Scheerens, Heleen, Lim, Jeremy, Cai, Fang, Kishnani, Mona, Liao, X. Charlene, Samineni, Divya, Zhu, Rui, Cochran, Colette, Soong, Weily, Diaz, Joseph D., Perin, Patrick, Tsukayama, Miguel, Dimov, Dimo, Agache, Ioana, Kelsen, Steven G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797126/
https://www.ncbi.nlm.nih.gov/pubmed/26993628
http://dx.doi.org/10.1186/s12931-016-0347-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4797126/
https://www.ncbi.nlm.nih.gov/pubmed/26993628
http://dx.doi.org/10.1186/s12931-016-0347-2

Ejemplares similares